Clinical Trials Logo

Filter by:
NCT ID: NCT05008874 Active, not recruiting - AMN Clinical Trials

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia

CYGNET
Start date: June 21, 2021
Phase:
Study type: Observational

The course of AMN-related disabilities over time is poorly or incompletely understood due to a limited number of patients and lack of treatments. This study will help obtain a better understanding of the progression of disease with AMN and facilitate efficient clinical development of future interventional medications.

NCT ID: NCT05008523 Active, not recruiting - Opioid Overdose Clinical Trials

Opioids and Police Safety Study

OPS
Start date: January 22, 2021
Phase: N/A
Study type: Interventional

Overdose deaths are currently the largest cause of accidental death in the US and opioid-related overdose deaths constitute the overwhelming majority of these deaths. Demands for a knowledge-base for effective law enforcement interventions is growing. This proposed study is designed to provide a knowledge base regarding key obstacles and facilitators of the willingness and preparedness of police to administer naloxone and related risk reduction practices and evaluate the efficacy of a web-based opioid-related occupational safety and risk reduction curriculum. Findings from this study will be applied to the development and implementation of effective interventions for police officers aimed at harmonizing law enforcement practices with public health goals.

NCT ID: NCT05008484 Active, not recruiting - Spinal Cord Injury Clinical Trials

Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.

Start date: October 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Neurogenic osteoporosis is a common complication of spinal cord injury (SCI) that is associated with low impact bone fractures. It is concerning that more than 46,000 Veterans affected with SCI and are at risk of osteoporosis and possible low impact fractures. About fifty percent of all individuals with SCI will develop low impact fracture in their life time. The management of osteoporosis-related fractures can impose substantial economic burden on the health care system, the individual and the families. Previous studies did not succeed in reversing the process of bone loss after SCI. In the present pilot study, we will evaluate the effect of Neuromuscular Electrical Stimulation Resistance Training in combination with oral Vitamin D supplementation, on bone quality in Veterans with chronic SCI, using a randomized experimental design.

NCT ID: NCT05008224 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

KEYNOTE-C11
Start date: October 7, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation. The primary hypothesis of the study is that the complete response (CR) rate at the end of study intervention according to Lugano 2014 response criteria is higher than conventional chemotherapy.

NCT ID: NCT05008055 Active, not recruiting - Clinical trials for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

CAPITAL
Start date: November 3, 2021
Phase: Phase 2
Study type: Interventional

This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

NCT ID: NCT05007925 Active, not recruiting - Clinical trials for Peripheral Artery Disease

Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System

Start date: November 18, 2021
Phase: N/A
Study type: Interventional

To assess the continued safety, effectiveness, and optimal clinical use of the Shockwave Medical Peripheral IVL System for the treatment of calcified, stenotic BTK arteries. Post-market, prospective , multi-center, single-arm study.

NCT ID: NCT05007301 Active, not recruiting - Diabetic Foot Ulcer Clinical Trials

Geko™ Cross Therapy Registry - Wound

CTR-Wound
Start date: April 4, 2022
Phase:
Study type: Observational [Patient Registry]

The geko™ Cross Therapy REGISTRY - Wound is a prospective, observational, anonymised data collection Registry with no experimental treatment that will fulfil an unmet need for an observational Registry to provide long-term clinical data to demonstrate patient benefit and regulatory compliance.

NCT ID: NCT05006833 Active, not recruiting - HPV Clinical Trials

Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness

Text&Talk
Start date: November 18, 2021
Phase: N/A
Study type: Interventional

This study will test the effectiveness of two interventions (parent-targeted text messages and a brief clinician-targeted training) at increasing HPV vaccination among 11- to 12-year-olds living in Florida.

NCT ID: NCT05006443 Active, not recruiting - Clinical trials for Tricuspid Regurgitation

Staging Classification of Severe Tricuspid Regurgitation Using Novel Cardiac Imaging Techniques

Start date: January 14, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to assess the severity of tricuspid regurgitation (a disorder in which the tricuspid valve in the heart does not close tight enough) using cardiac magnetic resonance imaging (MRI).

NCT ID: NCT05006352 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

Start date: August 11, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind study of 28 days, followed by an 18-month open-label extension, designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL343 in participants with amyotrophic lateral sclerosis (ALS)